Resources
Research

CLARITY 12-Month Study

December 31, 2023
Copy URL

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

LinkedIn
X
CLARITY Study Shows Positive Long-Term Results from Study on Chronic Rhinitis Treatment. Click the button below to read more.

‍

See Full ArticleSee Full Article
Share this post
Copy URL

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

LinkedIn
X

Our Newsletter

Subscribe to our newsletter to stay informed on the latest news and updates

I want to receive information and updates for:
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Get connected with the PNN Collective - Join the Conversation

Breathing better means feeling better.

If you’re ready to put the frustration, annoyance, and embarrassment of Chronic Rhinitis behind you and start living your best life, find a provider in your area today.

Find a Provider

Related Content

Press Release & News
For Patients
For Providers
Investors

NEUROMARK® Now with Expanded Access on UnitedHealthcare’s Medicare Advantage Policy for Posterior Nasal Nerve Ablation

Effective immediately, CPT 31242 is no longer considered experimental, removing a key barrier for ENT physicians treating chronic rhinitis.

Neurent News
•
•
Press Release & News
For Patients
For Providers
Investors

NEUROMARK® Treatment for Chronic Rhinitis Demonstrates Durable 2-Year Clinical Benefits

Neurent Medical announced that its PARAGON study demonstrated durable two-year efficacy and safety of the NEUROMARK® System, with patients experiencing significant and sustained improvements in chronic rhinitis symptoms and quality of life. Results, published in Ear, Nose, & Throat Journal, confirm NEUROMARK’s transformative potential for both allergic and nonallergic rhinitis patients.

Neurent News
•
NEUROMARK TECHNOLOGY
•
Press Release & News
For Patients
For Providers
Investors

Neurent Medical Announces Expanded Access Following Cigna Policy Update for NEUROMARK®

We’re proud to share that Cigna Healthcare has officially removed CPT 31242 posterior nasal nerve ablation using radiofrequency from its Experimental & Investigational (E&I) list, effective September 15, 2025.

Neurent News
•
•
View ALl Resources